Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone949-297-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$858.29 million
Profitability
Miscellaneous
Employees1,500
Next Earnings Date2/19/2020 (Confirmed)
OptionableOptionable
Masimo (NASDAQ:MASI) Frequently Asked Questions
What is Masimo's stock symbol?
Masimo trades on the NASDAQ under the ticker symbol "MASI."
How were Masimo's earnings last quarter?
Masimo Co. (NASDAQ:MASI) posted its quarterly earnings data on Wednesday, October, 30th. The medical equipment provider reported $0.76 EPS for the quarter, topping the consensus estimate of $0.73 by $0.03. The medical equipment provider earned $229.01 million during the quarter, compared to analyst estimates of $221.92 million. Masimo had a net margin of 20.83% and a return on equity of 17.32%. Masimo's quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.71 earnings per share. View Masimo's Earnings History.
When is Masimo's next earnings date?
How can I listen to Masimo's earnings call?
Masimo will be holding an earnings conference call on Wednesday, February 19th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Masimo issued on next quarter's earnings?
Masimo issued an update on its FY 2019
Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of 3.18 for the period, compared to the Thomson Reuters consensus estimate of $3.17. The company issued revenue guidance of $934-937 million, compared to the consensus revenue estimate of $947.01 million.
What price target have analysts set for MASI?
6 analysts have issued 12-month target prices for Masimo's stock. Their forecasts range from $134.50 to $190.00. On average, they expect Masimo's share price to reach $167.08 in the next year. This suggests that the stock has a possible downside of 1.2%. View Analyst Price Targets for Masimo.
What is the consensus analysts' recommendation for Masimo?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Masimo.
What are Wall Street analysts saying about Masimo stock?
Here are some recent quotes from research analysts about Masimo stock:
- 1. According to Zacks Investment Research, "Masimo exited the first quarter on a robust note. The company continues to gain from its key Product segment, which witnessed solid growth in the quarter. Notably, the company’s non-invasive technology shipments surged in the quarter. Raised guidance for 2019 buoys optimism as well. Management is optimistic about Masimo’s recent initiative for hospital automation. The company recently launched its Iris Device Management System in the United States. Additionally, Masimo has launched Doctella to boost its remote care automation platform. Shares of Masimo outperformed the industry in a year’s time. Meanwhile, Masimo’s Royalty and Other segment witnessed significant softness in the quarter. In fact, management anticipates no meaningful contribution from the unit in 2019. Furthermore, Masimo expects foreign currency headwinds in 2019 to impact the top line. The company faces fierce competition from MedTech bigwigs." (5/8/2019)
- 2. Needham & Company LLC analysts commented, "We hosted investor meetings with Kammerman, this week in the Midwest. We come away from the meetings with a better appreciation of MASI’s growth and margin outlook. We believe that MASI’s business model and product portfolio should enable it to sustain strong and consistent top and bottom line growth. Additionally, we think that the impact of the Philips agreement should cumulatively build as boards with MASI’s Rainbow and other measurements are installed in an increasing portion of Philips’ installed base. And we see several catalysts (detailed below) that could help MASI shares in 2019. Given all of this, we reiterate our Buy rating." (2/1/2019)
Has Masimo been receiving favorable news coverage?
News coverage about MASI stock has been trending extremely negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Masimo earned a daily sentiment score of -4.5 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Masimo.
Are investors shorting Masimo?
Masimo saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,530,000 shares, an increase of 166.3% from the December 31st total of 574,600 shares. Based on an average trading volume of 293,700 shares, the days-to-cover ratio is currently 5.2 days. Currently, 3.1% of the company's stock are sold short. View Masimo's Current Options Chain.
Who are some of Masimo's key competitors?
Some companies that are related to Masimo include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).
What other stocks do shareholders of Masimo own?
Who are Masimo's key executives?
Masimo's management team includes the folowing people:
- Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 54)
- Mr. Micah Young, Exec. VP of Fin. & CFO (Age 40)
- Mr. Anand Sampath, Chief Operating Officer (Age 53)
- Dr. Steven J. Barker, Chairman of Scientific Advisory Board, Chief Science Officer & Director (Age 74)
- Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 46)
Who are Masimo's major shareholders?
Masimo's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.40%), Boston Trust Walden Corp (0.25%), New York State Teachers Retirement System (0.13%), Mckinley Capital Management LLC Delaware (0.06%), Forte Capital LLC ADV (0.04%) and Cardinal Capital Management (0.03%). Company insiders that own Masimo stock include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Institutional Ownership Trends for Masimo.
Which institutional investors are selling Masimo stock?
MASI stock was sold by a variety of institutional investors in the last quarter, including B & T Capital Management DBA Alpha Capital Management, State of Alaska Department of Revenue, FinTrust Capital Advisors LLC, Cardinal Capital Management, Janney Montgomery Scott LLC, Eukles Asset Management, Valeo Financial Advisors LLC and NEXT Financial Group Inc. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Bilal Muhsin, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Insider Buying and Selling for Masimo.
Which institutional investors are buying Masimo stock?
MASI stock was acquired by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware, Forte Capital LLC ADV, Scout Investments Inc., Boston Trust Walden Corp, Strs Ohio, Patten Group Inc., Bowling Portfolio Management LLC and Red Spruce Capital LLC. View Insider Buying and Selling for Masimo.
How do I buy shares of Masimo?
Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Masimo's stock price today?
One share of MASI stock can currently be purchased for approximately $169.08.
How big of a company is Masimo?
Masimo has a market capitalization of $9.02 billion and generates $858.29 million in revenue each year. The medical equipment provider earns $193.54 million in net income (profit) each year or $3.03 on an earnings per share basis. Masimo employs 1,500 workers across the globe.View Additional Information About Masimo.
What is Masimo's official website?
How can I contact Masimo?
Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]
MarketBeat Community Rating for Masimo (NASDAQ MASI)
MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
